Generated by All in One SEO v4.9.10, this is an llms.txt file, used by LLMs to index the site.

# Neurolentech website

Precision Medicine for Neurodevelopmental Disorders

## Sitemaps

- [XML Sitemap](https://neurolentech.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Pages

- [Home page](https://neurolentech.com/) - Ethics-approved patient-derived neuronal models for drug discovery in epilepsy, intellectual disability, severe autism and other neurodevelopmental disorders.
- [Join us](https://neurolentech.com/join-us-page/) - JOIN US
- [Team](https://neurolentech.com/team/) - TEAM
- [Pipeline](https://neurolentech.com/pipeline/)
- [About](https://neurolentech.com/about-page/) - ABOUT US
- [Datenschutzerklärung](https://neurolentech.com/privacy-policy/) - Datenschutzerklärung neurolentech.com (the "Site") is owned and operated by Neurolentech GmbH. Neurolentech GmbH is the data controller and can be contacted at: contact@neurolentech.com ________________________________________ Neurolentech GMBH, Xista Science Park, Plöcking 1, 3400 Klosterneuburg, Austria Purpose The purpose of this privacy policy (this "Privacy Policy") is to inform users of our Site of the following: The
- [Contact](https://neurolentech.com/contact-page/)
- [News](https://neurolentech.com/news/) - NEWS
- [Press release](https://neurolentech.com/press-release/)

## news

- [Neurolentech Signs Technology Access Partnership with Kaerus Bioscience to Advance Neurodevelopmental Disorder Research](https://neurolentech.com/news/neurolentech-signs-technology-access-partnership-with-kaerus-bioscience-to-advance-neurodevelopmental-disorder-research/) - Kaerus Bioscience will access Neurolentech’s NDD Drug Discovery Platform to support development of its preclinical asset pipeline for numerous genetic syndromes Klosterneuburg, Austria, 22 April 2024: Neurolentech, a pioneering drug discovery startup spun out of IST Austria and focused on epilepsy and related genetic neurodevelopmental disorders (NDDs), today announced a technology access partnership with
- [From diagnostic odyssey to drug discovery: TESS Research Foundation’s Collaboration with Neurolentech](https://neurolentech.com/news/from-diagnostic-odyssey-to-drug-discovery-tess-research-foundations-collaboration-with-neurolentech/) - Kim Nye's rare disease journey began when she had her first child, Tessa, at the age of 23. Despite a normal pregnancy and clear test results during pregnancy, Tessa faced immediate health problems that puzzled doctors. This marked the start of a ten-year quest for answers and treatments by Kim and her husband, Zach. During
- [IST CUBE is a new investment partner](https://neurolentech.com/news/new-clinical-collaboration-partner-university-hospital-frankfurt-3/) - https://xista.vc/neurolentech-an-ist-austria-spin-off-company-tackling-autism-and-epilepsy-receives-seed-investment/ https://xista.vc/portfolio/detail/neurolentech
- [TESS Foundation invests in Neurolentech's approach for SLC13A5](https://neurolentech.com/news/new-clinical-collaboration-partner-university-hospital-frankfurt-5/)
- [Neurolentech receives Riz up genius award 2020](https://neurolentech.com/news/new-clinical-collaboration-partner-university-hospital-frankfurt-6/)
- [USP7 Foundation invests in Neurolentech](https://neurolentech.com/news/new-clinical-collaboration-partner-university-hospital-frankfurt-4/)
- [New clinical collaboration partner University hospital Frankfurt](https://neurolentech.com/news/new-clinical-collaboration-partner-university-hospital-frankfurt-2/)
- [New clinical collaboration partner Meyer hospital Florence](https://neurolentech.com/news/new-clinical-collaboration-partner-university-hospital-frankfurt/)

## press_release

- [University Hospital Frankfurt and Neurolentech GmbH announce clinical collaboration to produce cellular models for neurodevelopmental disordersUniversity Hospital Frankfurt and Neurolentech GmbH announce clinical collaboration to produce cellular models for neurodevelopmental disorders](https://neurolentech.com/press_release/meyer-hospital-florence-and-neurolentech-gmbh-announce-clinical-collaboration-to-produce-cellular-models-for-genetic-epileptic-encephalopathies-3/) - Frankfurt/Main - Germany; Klosterneuburg - Austria, August 8, 2022 – University Hospital Frankfurt (www.kgu.de) and Neurolentech GmbH (https://neurolentech.com) today announced a new collaboration to generate patient-specific cellular models for neurodevelopmental disorders such as Autism Spectrum Disorder(ASD). Their aim is to investigate disease mechanisms at the cellular, functional and molecular level with the goal to develop
- [Meyer Hospital Florence and Neurolentech GmbH announce clinical collaboration to produce cellular models for genetic epileptic encephalopathies](https://neurolentech.com/press_release/meyer-hospital-florence-and-neurolentech-gmbh-announce-clinical-collaboration-to-produce-cellular-models-for-genetic-epileptic-encephalopathies-2/) - Florence - Italy; Klosterneuburg - Austria, August 8, 2022 – Meyer Hospital Florence (https://www.meyer.it/) and Neurolentech GmbH (https://neurolentech.com) today announced a new collaboration to generate patient-specific cellular models for genetic epileptic encephalopathies. Their aim is to investigate disease mechanisms at the cellular, functional and molecular level with the goal to develop tools and generate data